In 2023, the Hong Kong stock market's 18A segment celebrated its fifth year of listing, and the fifth set of standards for the Sci-tech Innovation Board welcomed its fourth year of operation. A total of 85 biotech companies have successfully gone public through this listing channel, driving the entire life sciences sector into high gear. Having experienced both a boom and pursuit, as well as a cold winter and rationality, life sciences companies have never stopped innovating and breaking through. They continuously inject development momentum through technological innovation and bridge gaps through business model innovation. After experiencing dark moments, they still see themselves standing at new starting points and forging ahead.
From September 27th to 28th, Frost & Sullivan (Frost & Sullivan, abbreviated as F&S) will host its second New Investment Expo and the 17th Frost & Sullivan Global Growth, Sci-tech Innovation and Leadership Summit (abbreviated as "F&S New Investment Conference") at the Shangri-La Hotel in Pudong, Shanghai. The conference will grandly introducethe New Life Sciences Investment Summit Forumwith the theme of“New Directions for the Future &mdquo; andgatheringindustry leaders, life sciences companies, investment institutions, and professional service providersto focus on new opportunities in life sciences investment and financing, and jointly discuss the capital and industrial forces for companies to navigate through cycles.
We sincerely invite you to attend this forum and embark on the successful journey of the capital market for life sciences companies!
Time:September 27th - 28th, 2023
Venue:Shangri-La Hotel in Pudong, Shanghai
Sponsors:Frost & Sullivan and the China Biomedical Industry Chain Innovation and Transformation Alliance (CBIITA)
About Fukang Pharmaceutical
Fukang (Shanghai) Health Technology Co., Ltd. is a new drug R&D enterprise based in China and facing the global market, dedicated to developing innovative drugs in the fields of oncology and aging diseases. Guided by unmet clinical medication needs in China and globally, the company designs and develops original innovative drugs with "First-in-Class" or "Best-in-Class" potential and enters the international pharmaceutical market to provide patients with better treatment options. Fukang's headquarters is located in Shanghai, with offices established in Guangzhou, Wuhan, Boston, and other places. The company holds over a hundred global invention patents and is currently a national specialized and refined small giant enterprise, a high-tech enterprise in Shanghai, a specialized and refined enterprise in Shanghai, and a patent pilot enterprise in Shanghai. Its product pipeline covers solid tumors and hematological tumors that urgently need innovative treatment plans at home and abroad, including breast cancer, prostate cancer, pancreatic cancer, liver cancer, gastric cancer, lung cancer, etc.
Introduction to Speakers
Shen Xiaokun graduated from the School of Medicine at Wuhan University with dual degrees in clinical medicine and bioscience, and obtained a Doctor of Pharmacy degree from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has successively engaged in the R&D of new small molecule and antibody drugs at well-known domestic and international companies such as Hengrui and Novartis, with over ten years of experience in new drug R&D. He has led and participated in the clinical development of new drugs for various diseases such as anti-tumor, immunology, and dermatology, and has helped multiple drugs successfully go public in China, including the First-in-Class IL-17 antibody Cosentyx.
Founded Fukang Pharmaceutical in 2018, it has received multiple rounds of investment from well-known institutions such as WuXi AppTec and Jiuzhou Tong Venture Capital. The company develops new therapies with "First-in-Class" and "Best-in-Class" potential, layouts a new generation of dual antibody and differentiated small molecule combination technology platforms, empowers new drug discovery with AI technology platforms, gives full play to the advantages of drug R&D and clinical development, and provides innovative treatment plans for a large number of cancer patients. Its product pipeline is rich and has differentiated competitive features, covering solid tumors and hematological tumors such as breast cancer, prostate cancer, pancreatic cancer, liver cancer, gastric cancer, lung cancer, etc., including the second-generation PARP inhibitor CVL218 that has shown "Best-in-Class" potential, the globally competitive PI3K β/δ dual high-selectivity inhibitor CVL237, and the "First-in-Class" potential bispecific antibody B006.
01
Consultation on Participation
Registration Consultation | Business Cooperation | Media Cooperation
Contact Person:
Ms. Li 18917935734 (same WeChat)
Ms. Bai 18019047843 (same WeChat)
02
Highlights from the Previous Session
